Patient consent to publication and data sharing in industry and NIH-funded clinical trials

被引:14
作者
Spence, O'Mareen [1 ]
Uba, Richie Onwuchekwa [2 ]
Shin, Seongbin [1 ]
Doshi, Peter [1 ]
机构
[1] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[2] Notre Dame Maryland Univ, Baltimore, MD USA
关键词
Informed consent; Ethics; Responsible conduct of research; Publication bias; Reporting bias; Data sharing; Clinical trials; Clinical data;
D O I
10.1186/s13063-018-2651-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Participants are recruited into clinical trials under the assumption that the research will contribute to medical knowledge. Therefore, non-publication trials-and, more recently, lack of data sharing-are widely considered to violate the trust of trial participants. Existing practices regarding patient consent to publication and data sharing have not been evaluated. Analyzing informed consent forms (ICFs), we studied what trial participants were told regarding investigators' intention to contribute to medical knowledge, publish trial results, and share de-identified trial data. Methods: We obtained 98 ICFs of industry-funded pre-marketing trials for all (17) antibiotics approved by the European Medicines Agency and 46 ICFs of publicly funded trials from the National Heart, Lung and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) data repository. Three authors independently reviewed ICFs to identify and extract what was stated or implied regarding: (1) publication of results; (2) sharing de-identified data; (3) data ownership; (4) confidentiality of identifiable data; and (5) whether the trial will produce knowledge that offers public benefit. Consensus was obtained from the two reviewers with the greatest overall agreement on all five measures. Disagreements were resolved through discussion among all authors. Results: Four (3%) trials indicated a commitment to publish trial results; 140 (97%) did not commit to publishing trial results; six (4%) indicated a commitment to share de-identified data with third party researchers. Commitments to share were more common in publicly funded trials than industry-funded trials (7% vs 3%). A total of 103 (72%) ICFs indicated the trials will or may produce knowledge that offers public benefits, while 131 (91%) ICFs left unstated who "owned" trial data; of those with statements, the sponsor always claimed ownership. Patient confidentiality was guaranteed in 137 (95%) trials. Conclusions: Our results suggest that consent forms rarely disclose investigators' intentions regarding the sharing of de-identified data or publication of trial results.
引用
收藏
页数:5
相关论文
共 22 条
[11]   Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy [J].
Jenkins, V ;
Fallowfield, L .
BRITISH JOURNAL OF CANCER, 2000, 82 (11) :1783-1788
[12]   Patient Perspectives on Sharing Deidentified Trial Data [J].
Jones, Christopher W. ;
Roberts, Brian W. ;
Platts-Mills, Timothy F. .
ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) :748-749
[13]   Biomedical research: increasing value, reducing waste [J].
Macleod, Malcolm R. ;
Michie, Susan ;
Roberts, Ian ;
Dirnagl, Ulrich ;
Chalmers, Iain ;
Ioannidis, John P. A. ;
Salman, Rustam Al-Shahi ;
Chan, An-Wen ;
Glasziou, Paul .
LANCET, 2014, 383 (9912) :101-104
[14]   Decision-making and breast cancer clinical trials -: How experience challenges attitudes [J].
Mancini, Julien ;
Geneve, Jean ;
Dalenc, Florence ;
Genre, Dominique ;
Monnier, Alain ;
Kerbrat, Pierre ;
Largillier, Remy ;
Serin, Daniel ;
Rios, Maria ;
Roche, Henri ;
Jimenez, Marta ;
Tarpin, Carole ;
Reynier, Claire Julian .
CONTEMPORARY CLINICAL TRIALS, 2007, 28 (06) :684-694
[15]   The Common Rule, Updated [J].
Menikoff, Jerry ;
Kaneshiro, Julie ;
Pritchard, Ivor .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :613-615
[16]  
National Commission For The Protection of Human Subjects, 1978, REP NAT COMM PROT HU
[17]  
National Heart Lung and Blood Institute, 2017, BIOL SPEC DAT REP IN
[18]  
PhRMA EFPIA, 2013, PRINC RESP CLIN TRIA
[19]   Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study [J].
Prayle, Andrew P. ;
Hurley, Matthew N. ;
Smyth, Alan R. .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
[20]   Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation [J].
Rising, Kristin ;
Bacchetti, Peter ;
Bero, Lisa .
PLOS MEDICINE, 2008, 5 (11) :1561-1570